FINAL (2)-150.png
BackTABLEfinal-2tone_edited.png

© 2020 by Backtable. All rights reserved.

Episode 67

Locoregional Therapies for Bridging to Transplant in HCC

with Dr. Alex Kim and Dr. Christopher Beck

BackTable, LLC (Producer). (2020, June 8). Ep. 67 – Locoregional Therapies for Bridging to Transplant in HCC [Audio podcast]. Retrieved from https://www.backtable.com/podcasts

Interventional Radiologist Dr. Alex Kim and Dr. Christopher Beck discuss the utility of different locoregional liver therapies in bridging HCC patients to transplant.

Special thanks to our sponsor

Podcast Participants

Dr. Alex Kim is a practicing Interventional Radiologist at MedStar Georgetown University Hospital in Washington D.C.

Host Dr. Chris Beck is a practicing interventional radiologist with Regional Radiology Group in New Orleans.

---

TriSalus Infusion Systems

TriSalus Life Sciences is dedicated to improving patient outcomes in HCC and other highly intractable solid tumors. TriSalus Infusion Systems have the potential to deliver diagnostic, therapeutic, and immuno-stimulant agents directly into the tumor vascular, powered by their proprietary pressure-enabled delivery approach.

TriSalus Life Sciences Sponsorship on BackTable

Show Notes

Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693‐699. doi:10.1056/NEJM199603143341104 - Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394‐1403. doi:10.1053/jhep.2001.24563 - Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival

DiNorcia J, Florman SS, Haydel B, et al. Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium. Ann Surg. 2020;271(4):616‐624. doi:10.1097/SLA.0000000000003253 - Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma

Shi L, Wang J, Ding N, et al. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nat Commun. 2019;10(1):5421. Published 2019 Nov 28. doi:10.1038/s41467-019-13204-3 - Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy

Kim AY, Miller A. Evaluation of Surefire's precision direct-to-tumor embolization device to augment therapeutic response to intra-arterial, liver-directed therapies for patients with primary and secondary liver cancers. Expert Rev Med Devices. 2016;13(5):435‐443. doi:10.1586/17434440.2016.1164594

Kim AY, Frantz S, Krishnan P, et al. Short-term imaging response after drug-eluting embolic trans-arterial chemoembolization delivered with the Surefire Infusion System® for the treatment of hepatocellular carcinoma. PLoS One. 2017;12(9):e0183861. Published 2017 Sep 1. doi:10.1371/journal.pone.0183861

Cheng A-L, Qin S, Ikeda M, et al. IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).Ann Oncol. 2019;30(suppl 9):ix186-ix187. doi: 10.1093/annonc/mdz446.002. - IMbrave150: efficacy and safety results

National Comprehensive Cancer Network: https://www.nccn.org/

Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734-9. - Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma

Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164-71. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

Podcast Transcript

This transcript is not yet available.

Join The Discussion

Related Content

No related content.

Demo Video

Reflux Control Microcatheter Designed Using Flow Dynamic Principals, Creating a Fluid Barrier

Podcast

Pressure-Directed Therapy in TACE

Podcast

Bridging to Transplant for HCC

Podcast

Targeting the Tumor Microenvironment in HCC

Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

 
TriSalus Infusion System on BackTable

Submit this form to get in touch with a rep and learn more about treating solid tumors with TriSalus Infusion Systems.

TriSalus Infusion System on BackTable